Objectives: The antimicrobial susceptibility of Neisseria gonorrhoeae isolates from Saskatchewan was determined retrospectively to ascertain temporal trends to both current and older antimicrobials used for treatment.
Introduction
Neisseria gonorrhoeae is an obligate human pathogen causing gonorrhoea, a disease with 78 million new cases worldwide (2012 data). 1 The actual numbers of gonorrhoea infections are undoubtedly higher; cases can be drastically under-reported due to poor reporting systems, lack of clinical or laboratory diagnostic capability and high rates of asymptomatic infection, particularly in women (as high as 50%). 1, 2 There are no vaccines against N. gonorrhoeae; gonorrhoea infections can only be cured by treatment with antibiotics. N. gonorrhoeae can acquire new resistance mechanisms fairly soon after a new antimicrobial is introduced for treatment and can become potentially resistant to every class of antimicrobial. 2, 3 Over time, N. gonorrhoeae has developed resistance to all antibiotics previously recommended for treatment. 1 The WHO and many countries, including Canada, now recommend extendedspectrum cephalosporins, i.e. ceftriaxone or cefixime, and azithromycin co-therapy, as the first-line empirical treatment of N. gonorrhoeae infections. [4] [5] [6] Isolates with co-resistance to both ceftriaxone and azithromycin have been reported from Canada and treatment failure after this dual therapy has been noted. 7, 8 Gonorrhoea has been a notifiable disease in Canada since 1924 and is the second most commonly reported bacterial sexually transmitted infection after Chlamydia trachomatis infections. 9 The reported incidence of gonococcal infections in Canada increased from 26 to 36.2 cases/100000 between 2003 and 2012. 10 The rate of gonorrhoea in Saskatchewan in 2012 was 93.6 per 100000, 2.6 times higher than national rates. 10 Historically, gonococcal isolates in Saskatchewan have been V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. susceptible to antibiotics. In a national study conducted in 1988-89, the prevalence of resistance to penicillin and tetracycline in Saskatchewan was low, i.e. 0%-0.9% and 0%-2.7%, respectively. 11 Since then, no longitudinal study has been designed to determine the status of N. gonorrhoeae antimicrobial resistance in the province. 10, 12 The goal of this study was to ascertain retrospectively the prevalence, patterns and trends of antimicrobial resistance in N. gonorrhoeae isolates from Saskatchewan (2003-15) to currently and previously recommended antibiotics.
Materials and methods

Isolation and identification of N. gonorrhoeae isolates
Cultures of N. gonorrhoeae (n " 685) were collected consecutively at the Saskatchewan Disease Control Laboratory, Regina, Saskatchewan between 2003 and 2015. None of the isolates tested were duplicate specimens from the same patient over this period. Primary isolation and identification of N. gonorrhoeae were completed as described previously. 13 Isolates were stored at #80 C in Difco TM brain heart infusion medium (BD Biosciences, Oakville, ON, Canada) containing 20% glycerol. Frozen stocks of N. gonorrhoeae isolates were retrieved on Difco TM GC Agar Medium Base (BD Biosciences), supplemented with 1% modified Kellogg's supplement and incubated at 35 C with 5%-7% CO 2 in a humid environment for 20-24 h. 13, 14 Isolates were reconfirmed as N. gonorrhoeae using the oxidase test and Gram staining.
14 The Saskatchewan Disease Control Laboratory provided data on geographical locations, anatomical sites of isolation and gender of clients.
Antimicrobial susceptibility testing
The MICs of penicillin, tetracycline, ciprofloxacin, azithromycin, cefixime, ceftriaxone and spectinomycin for the N. gonorrhoeae isolates were determined, in duplicate, using the agar dilution method of the CLSI.
14 WHO strains B, C, F and K and ATCC 49226 were used as reference strains for antimicrobial susceptibility testing and antibiotics were purchased from SigmaAldrich (Oakville, ON, Canada). [14] [15] [16] MIC testing was quality assured through the national gonococcal antimicrobial surveillance quality assurance programme. 17 b-Lactamase production was detected using nitrocefin (Calbiochem, EMD Chemicals Inc., Darmstadt, Germany). Antimicrobial resistance criteria were those of the CLSI.
14 Azithromycin resistance was defined as an MIC 2 mg/L. 18 The resistance phenotypes determined in this study included: penicillinase-producing N. gonorrhoeae (PPNG; b-lacta- 18, 19 MDR and XDR N. gonorrhoeae were classified following guidelines of the National Microbiology Laboratory, Winnipeg, Canada, using a modification to previous classifications. 20 MDR is defined as resistance to one category I antibiotic (i.e. ceftriaxone, cefixime, azithromycin and spectinomycin) and to two or more category II antibiotics (penicillin, tetracycline, ciprofloxacin). XDR N. gonorrhoeae are characterized by resistance to two or more antibiotics in category I and to two or more antibiotics in category II.
Fisher's exact test was used to compare the proportion of isolates with resistance to tested antimicrobials in 2003 with other years of the study. Significance was set at a P value of ,0.05.
Molecular strain typing
Gonococcal STs were determined using the N. gonorrhoeae multiantigen sequence typing (NG-MAST) scheme; DNA sequences of porB and tbpB were determined as described previously and were submitted to the NG-MAST website (http://www.ng-mast.net/) to determine STs. (n " 655) of 0.5 mg/L indicates that the majority of isolates tested over the period were susceptible to azithromycin (data not shown). Azithromycin resistance was .5% in 2010 (27.6%) and 2013 (7.2%) only. Most (87.5%, 14 of 16) of the azithromycin-resistant isolates were recovered in Regina where the prevalence of these isolates overall was 6.3% (14 of 222, P " 0.0001). This was significantly higher than in the rest of the province (0.4%, 2 of 463, P " 0.0001). No azithromycin-resistant isolates were detected in Saskatoon or Prince Albert (Figure 3) . The NG-MAST determined STs of eight azithromycin-resistant isolates recovered in Regina in 2010 were ST688 (n " 6), ST1967 (n " 1) and ST3367 (n " 1). One isolate had CFM red and one isolate had CRO red , whereas one was less susceptible to both the antibiotics. These isolates were detected in 2012 and 2013. Azithromycin resistance was .5% only in Regina. Penicillin and ciprofloxacin can be used for treatment in Prince Albert as resistance rates were ,5%. N. gonorroheae isolates from other parts of the province were highly susceptible (.95%) to azithromycin and penicillin. Gonococcal susceptibility to new and older antibiotics JAC in Regina (32 of 222, 14.4%, P " 0.002) followed by Saskatoon (13 of 186, 7.0%). No penicillin resistance was detected in isolates from Prince Albert (Figure 3 ).
Antimicrobial susceptibility Ceftriaxone
Ciprofloxacin
Tetracycline
The percentage of tetracycline-resistant isolates remained .5 throughout the study period. In 2003, the prevalence of tetracycline resistance was 51.6% (31 of 60; Figure 2d ). Overall gonococcal tetracycline resistance ranged from 11.8% (4 of 34 
Resistance profiles, MDR and XDR isolates
Overall, 21 different resistance phenotypes were observed in the 685 N. gonorrhoeae isolates tested (Table 1) . Forty-one per cent (n " 282) were susceptible to all antibiotics and 326 (47.6%) isolates were resistant to one antibiotic [i.e. CMTR (38.4%), TRNG Four (0.6%) isolates were characterized as MDR [resistance to one category I antibiotic (includes third-generation cephalosporins and azithromycin) plus resistance to two or more category II antibiotics] as they were resistant to either azithromycin (n " 3) or ceftriaxone (n " 1) as well as two other antibiotics. Two (0.3%) isolates were characterized as XDR (resistance to two or more category I antibiotics plus resistance to two or more category II antibiotics) and these isolates carried either decreased susceptibility to ceftriaxone and cefixime (n " 1) or decreased susceptibility to cefixime and resistance to azithromycin (n " 1) plus were resistant to two or more other antibiotics (Figure 4b ). In summary, N. gonorrhoeae isolates with decreased susceptibility to extendedspectrum cephalosporins (n " 3; 0.6%) were either MDR (n " Discussion N. gonorrhoeae isolates from Saskatchewan are highly susceptible to the antibiotics (ceftriaxone, cefixime, azithromycin and spectinomycin) currently recommended for the treatment of gonorrhoea and resistance rates to antibiotics previously recommended for treatment, i.e. penicillin and ciprofloxacin, were lower as compared with other Canadian data. 10, [22] [23] [24] Only three (0.4%) isolates displayed CFM red and/or CRO red , respectively. By comparison, 7.6% of Canadian N. gonorrhoeae isolates displayed decreased susceptibility to ceftriaxone and/or cefixime in 2011, decreasing to 3.1% in 2014. 25, 26 Europe reported 4.7% (2013) of N. gonorrhoeae isolates tested having cefixime MICs .0.125 mg/L as compared with 2.0% in 2014. 27 In the USA, CFM red and CRO red was 0.8% and 0.1%, respectively, in 2014. 18 N. gonorrhoeae isolates from Saskatchewan were susceptible (97.7%) to azithromycin, reflecting the low percentage of azithromycin-resistant isolates (3.3% in 2014) in Canada. 25, 26 No isolate with high-level (MIC 256 mg/L) resistance to azithromycin was detected in Saskatchewan. High-level azithromycin resistance (MIC .256 mg/L) to N. gonorrhoeae has been reported from various parts of the world, including the UK, Italy, Argentina, Ireland, Canada, China, Australia and the USA. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] The percentage of azithromycin-resistant isolates in the USA was 2.5% in 2014 and ranged from 5.4% (2013) to 7.9% (2014) in Europe. 18, 27 Azithromycin (1 g) with ceftriaxone (250 mg) or cefixime (800 mg) is recommended in Canada for the treatment of uncomplicated gonorrhoea. [4] [5] [6] In some countries, azithromycin alone (2 g) is used to treat gonococcal infections, 4 but treatment failures have been reported. 38, 39 A recent report on a treatment failure of gonorrhoea with ceftriaxone and azithromycin co-therapy has again raised concerns about restricted treatment options for gonorrhoea. 8 Azithromycin is also recommended for the treatment of C. trachomatis infections (1 g dose) in Canada, a regimen that may expose N. gonorrhoeae to suboptimal concentrations leading to resistance. 40, 41 In Regina, 45% of the clients with sexually transmitted infection were coinfected with N. gonorrhoeae and C. trachomatis. 42 Regina also experienced a sudden increase in azithromycin-resistant N. gonorrhoeae isolates in 2010, largely attributable to NG-MAST ST688.
Spectinomycin, an alternative regimen for treating urogenital gonorrhoea infections, is available under Health Canada's Special Access Program. 5 Since the 1990s, spectinomycin-resistant gonococcal isolates have not been reported in Canada and few resistant isolates have been reported globally. 2, 25 These resistant isolates were reported from the Netherlands (n " 1, 1975), Philippines (n " 1, 1981), South Korea (n " 8, 1987 ) and the UK (n " 3, 1982; n " 10, 1983). [43] [44] [45] [46] [47] Ciprofloxacin-resistant N. gonorrhoeae isolates ranged between 6.3% (2004) and 35.9% (2010) of isolates tested in Canada. 25 In the USA, ciprofloxacin resistance ranged from 9.6% (2009) 10, 18, 25, 49 Rural areas of the Northern Territories, Australia, and the Pacific Islands report gonococcal penicillin resistance rates ,5.0%. 50, 51 Penicillin is still used in regions of Australia coupled with comprehensive molecular testing for resistance. 52, 53 A similar test strategy in Saskatchewan might allow the use of penicillin in regions with documented low percentages of resistant isolates.
Resistance to tetracycline in N. gonorrhoeae isolates from Saskatchewan was largely higher than the national rates. 10, 25 The endemic presence of tetracycline resistance might be attributed to the use of tetracycline or doxycycline to treat chlamydial infections. 39 Only a small number (n " 31) of isolates in our study were rectal (n " 20 of 685, 2.9%) or pharyngeal (n " 11 of 427, 1.6%). Although none of these isolates was resistant to currently recommended antibiotics, they carried resistance to multiple antibiotics. The pharynx is an ideal site for the transfer of resistance to N. gonorrhoeae from commensal Neisserria spp. 54 Antimicrobial agents often do not reach optimum concentrations in the oropharynx, enabling this site to act as a niche for the selection of more resistant isolates. 55 Many strategies are under consideration for combating antimicrobial resistance in N. gonorrhoeae, including the development and evaluation of new antimicrobials and extensive antimicrobial susceptibility monitoring through regional/national surveillance programmes. 19 Most cases of gonorrhoea in Saskatchewan (.95%) are diagnosed by nucleic acid testing and the availability of N. gonorrhoeae cultures for antimicrobial susceptibility testing has decreased. 25 As antimicrobial susceptibilities cannot be ascertained by nucleic acid testing, our data may underestimate the true extent of gonococcal antimicrobial resistance. Our research showed that many no longer recommended antibiotics (penicillin, ciprofloxacin) might still be effective in treating N. gonorrhoeae infections over many years. Even with the recent higher percentages of N. gonorrhoeae isolates resistant to penicillin and ciprofloxacin, 85% of isolates in Saskatchewan remains susceptible to these antibiotics. The development of molecular, or point-of-care, tests for pathogen diagnosis and simultaneous antimicrobial resistance detection seems like a logical next step for better diagnosis and prudent use of available antibiotics in the treatment of gonococcal infections. Novel technologies, such as inexpensive, rapid genome sequencing platforms to diagnose antimicrobial determinants may also change diagnostic and treatment paradigms. It is urgent that such strategies be tested in clinical contexts rapidly to mitigate gonorrhoea becoming untreatable in the future. 
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